theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Rheumatology

Macrophage activation syndrome   

Questions discussed in this category


Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
MAS has responded to anakinra in the past.
2 Answers available

How do you approach management of a patient with persistent EBV infection and MAS despite treatment with Rituximab, anakinra and canakinumab? 
Would you consider alternative B cell depleting therapies such as ofatumumab or ocrelizumab?
1 Answer available

What is the difference between Multisystem Inflammatory Syndrome in Adults (MIS-A) and MAS/HLH?
1 Answer available

Do you recommend using IL-1/IL-6 inhibitors in COVID-19 multisystem inflammatory syndrome in adults (MIS-A)?
1 Answer available
2363418491125498533


Papers discussed in this category


ACR Open Rheumatol, 2021 Aug 25
Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.

Annals of the rheumatic diseases, 2023 Jul 24
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).

Related Topics in Rheumatology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.